SB 1327 creates a new section in Missouri insurance law governing how cost-sharing is calculated under health benefit plans. The bill requires health carriers and pharmacy benefits managers to count amounts paid by or on behalf of an enrollee for medications that do not have a generic substitute toward the enrollee’s out-of-pocket maximum and other cost-sharing limits. It also prohibits carriers and PBMs from designing benefits or setting cost-sharing in a way that takes into account the availability of manufacturer or third-party cost-sharing assistance for those medications.
The bill includes special rules for health savings account-qualified high deductible health plans, allowing the new cost-sharing counting requirement to apply only after the federal minimum deductible is met, except for preventive care items and services. It preserves step therapy authority under existing Missouri law and excludes plans governed by the federal Labor Management Relations Act. The bill would apply only to health benefit plans entered into, amended, extended, or renewed on or after August 28, 2026.
Impact
If enacted, SB 1327 would amend chapter 376, RSMo, by adding section 376.448 and imposing new requirements on health carriers and pharmacy benefits managers operating in Missouri. It would affect how out-of-pocket maximums and cost-sharing accumulators are administered for certain prescription drugs, especially high-cost brand medications without generic alternatives, and could increase the speed at which enrollees reach plan limits when using assistance programs. The bill would also interact with federal tax rules for HSA-qualified plans and would not apply to ERISA/LMRA-covered plans, limiting its reach to state-regulated health benefit plans.
Sentiment
The available record shows no committee transcript or recorded votes, so there is no documented floor or committee debate to gauge sentiment directly. Based on the bill text, the measure appears consumer-protective and aimed at reducing the financial burden on patients using medications without generic substitutes. The absence of recorded opposition or amendments in the provided materials suggests no clear public controversy is captured here, though the policy could draw interest from insurers, PBMs, and employers because it changes benefit design and cost-sharing administration.
Contention
The main potential points of contention are likely to be the bill’s limits on how insurers and pharmacy benefits managers may structure cost-sharing, and its prohibition on considering the availability of cost-sharing assistance programs when setting benefits. Insurers and PBMs may view these provisions as restricting plan design flexibility and potentially increasing costs, while patient advocates would likely support them as preventing assistance from being offset by higher cost-sharing. Another possible issue is the interaction with federal HSA rules and the delayed applicability date, which indicate the bill was drafted to avoid conflicts with federal law and give plans time to adjust.